<DOC>
	<DOCNO>NCT00967928</DOCNO>
	<brief_summary>This Phase 1 , single-site , dose-escalation study conduct determine maximum tolerate dose ( MTD ) RAD001 part specify combination regimen .</brief_summary>
	<brief_title>Everolimus Dose Finding Study Stage IV Recurrent Cervical Cancer</brief_title>
	<detailed_description>This Phase 1 , single-site , dose-escalation study conduct determine MTD RAD001 part specify combination regimen . The combination regimen standard field whole pelvic RT combination cisplatin 40mg/m2 weekly RAD001 dose escalation daily start 5 mg qod , 5 mg qd , 10 mg qd period whole pelvic radiation therapy .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must least one measurable site disease accord Response Evaluation Criteria Solid Tumors criteria previously irradiate . Female patient age ≥18 year . Patient life expectancy least 12 week study start . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 study start . Patient diagnosis stage IV recurrent , nonresectable , cervical cancer study start . Patient receive prior chemotherapy . Patient adequate hematologic function : Absolute neutrophil count [ ANC ] ≥1500/μL Platelets ≥100,000/μL Hemoglobin &gt; 9g/dL Patient adequate renal function : Serum creatinine ≤ 2.0 mg/dL Calculated creatinine clearance ≥ 50 mL/min Patient adequate hepatic function : Serum bilirubin ≤1.5 x ULN ALT AST ≤2.5 × ULN ( ≤ 5 x ULN patient liver metastasis ) INR &lt; 1.5 ( &lt; 3 anticoagulant ) Patient fast serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . Patient able provide sign informed consent . Patient neuroendocrine small cell carcinoma cervix . Patient previously use biologic therapy VEGF , VEGFR , ErbB1/ErbB2 inhibitor . Patient currently receive anticancer therapy receive anticancer therapy within 4 week start study drug ( include chemotherapy , radiation therapy , antibody base therapy , etc. ) . Patient major surgery significant traumatic injury within 4 week start study drug ; patient recover side effect major surgery ( define require general anesthesia ) patient might require major surgery course study . Patient prior treatment investigational drug within precede 4 week study start . Patient receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Patients receive immunization attenuate live vaccine within one week study entry study period . Patients also avoid close contact people receive live vaccine treatment everolimus . Examples live vaccine : intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , TY21a typhoid vaccine . Patient known brain leptomeningeal metastasis . Patient malignancy within past 3 year except adequately treat squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition condition could affect participation study : Symptomatic congestive heart failure New York Heart Association Class III IV . Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease . Severely impaired lung function define spirometry diffuse capacity ( DLCO ) 50 % normal predict value and/or O2 saturation 88 % less rest room air . Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN . Active ( acute chronic ) uncontrolled severe infection . Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . Patient known history human immunodeficiency virus seropositivity . Patient impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . Patient active , bleeding diathesis . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial 8 week end treatment sex . Hormonal contraceptives acceptable sole method contraception . ( Women childbearing potential must negative urine serum pregnancy test within 7 day prior administration RAD001 . ) Patient receive prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . Patient known hypersensitivity RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) excipients . Patient history noncompliance medical regimen . Patient unwilling unable comply protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Stage IV Recurrent Cervical cancer</keyword>
</DOC>